Checkpoint Therapeutics Inc (CKPT) Stock Price, Quote & News

Company Profile

Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignanci...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Fax: 646 619 4950

Website: checkpointtx.com

Address:

95 Sawyer Road, Suite 110, Waltham, United States

TwongStocks Jun. 9 at 11:50 AM

$CKPT Unlike the US, there is no fixed date for drug approvals in Europe. This is due to built in "clock stops" during the evaluation process. Typically, most drugs get approved around 1 year after positive validation. The two year deadline for the CVR is protection in case the approval takes longer than usual or runs into any sort of delay. But if they do not run into any serious delays, then we may see UNLOXCYT approval by next summer.

1 · Reply

TwongStocks Jun. 9 at 11:08 AM

$CKPT CHMP has now begun evaluating UNLOXCYT (Cosibelimab) for approval in Europe. Start of evaluation is May 21, 2026. This is the date the UNLOXCYT MAA received positive validation. The $0.70 CVR will payout if UNLOXCYT is approved within 2 years (by May 21, 2028) and the approved dose is once every 3 weeks. You can confirm the start date here. Download the 'Applications for new human medicines under evaluation' for June 2026: https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation

0 · Reply

Tott2022 Apr. 30 at 12:22 PM

$CKPT I am guessing Sun are gonna wait it out … and not have to pay up

1 · Reply

TREBLALBERT Feb. 22 at 11:33 AM

$CKPT Sun has to submit UNLOXCYT's MAA in Europe by May 30, 2026.

1 · Reply

GJ_Rockabilt Jan. 30 at 11:34 AM

$CKPT Today is last day to sign up to for FREE Warrants with every Share of Cancer fighting $TPST . Acquisition in process. Do your own Due Diligence.

0 · Reply

FinSUN Jan. 3 at 11:27 PM

$MIST $CKPT why are you saying that?

1 · Reply

H3rc1y Dec. 17 at 11:16 AM

$MIST Was anyone here in $CKPT ? I'm getting a very very similar vibe here.

1 · Reply

EJNap Dec. 3 at 2:13 AM

$CKPT Hopefully they will submit for EMA approval soon. Surprised they will only start commercialization in 2026 🤔 https://trial.medpath.com/news/557f3510f2173f9e/fda-approves-updated-label-for-unloxcyt-based-on-long-term-data-showing-improved-outcomes-in-advanced-cutaneous-squamous-cell-carcinoma?__cf_chl_tk=Gz1CHGQt.jjB.jh7FzdQTyB6iASXP3_xJSwaC3zJQGM-1764726181-1.0.1.1-gPnmeEjeSTWUM7e02H8tYWStLS00Lz8mKq.lKKxsWXQ

1 · Reply

ZSchafes Dec. 1 at 3:38 AM

$ITRM this time last year I got a long awaited but underwhelming buyout for $CKPT. Hoping we can get one here soon for a couple bucks at least.

0 · Reply

Al_Paca Oct. 30 at 5:12 PM

$CKPT $ITRM quiet period can be rough

0 · Reply

Market Cap	370.71M
Revenue (ttm)	40,000.00
Net Income (ttm)	-56.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140,600.01%
Debt to Equity Ratio	0.00

Volume	8,666,800
Avg Vol	1,808,080
Day's Range	N/A - N/A
Shares Out	87.02M
Stochastic %K	85%
Beta	1.18
Analysts	Sell
Price Target	$4.45